Disulfiram is a recently identified covalent inhibitor of GSDMD pore formation [17, 23], and it exhibits therapeutic promise in experimental BPD by blocking GSDMD-mediated pore formation and attenuating inflammatory responses. The gene discussed is GSDMD; the disease is bronchopulmonary dysplasia.